Private equity firm Everstone has bought a 70% stake in Mumbai-based Rubicon Research, a drug delivery technology company, for Rs 220 crore (US$ 33 million). Along with a $20 million investment directly into the business, the deal includes acquiring stakes from Kotak Private Equity, and a private investor.
This is the fourth investment from Everstone's latest PE fund (Everstone Capital Partners III) and was led by Deep Mishra, an Everstone MD who focuses on consumer and pharmaceutical investments for the group. Deep will be joining the board of Rubicon, says a company statement.
Rubicon is a world-class outsourcing partner to the global pharmaceutical industry whose proprietary technologies provide solutions for bioavailability enhancement, gastric retention, taste masking, and customising the release profiles of drugs. Rubicon also offers lifecycle management services for pharmaceutical products.
Besides, Rubicon has a US FDA-approved manufacturing plant with a capacity of 800 million tablets and it has refocused its business on creating its own abbreviated new drug applications/new drug applications for the global market.
Courtesy:- TOI (Times of India).
This is the fourth investment from Everstone's latest PE fund (Everstone Capital Partners III) and was led by Deep Mishra, an Everstone MD who focuses on consumer and pharmaceutical investments for the group. Deep will be joining the board of Rubicon, says a company statement.
Rubicon is a world-class outsourcing partner to the global pharmaceutical industry whose proprietary technologies provide solutions for bioavailability enhancement, gastric retention, taste masking, and customising the release profiles of drugs. Rubicon also offers lifecycle management services for pharmaceutical products.
Besides, Rubicon has a US FDA-approved manufacturing plant with a capacity of 800 million tablets and it has refocused its business on creating its own abbreviated new drug applications/new drug applications for the global market.
Courtesy:- TOI (Times of India).
No comments:
Post a Comment